AstraZeneca ‘Particularly Pleased’ With Q1 China Performance

AstraZeneca put in another good performance in the emerging markets and China in the first quarter, albeit at lower growth rates than last year, and in contrast to some of its competitors sees continued bright prospects in the latter market in particular, given a well-suited product portfolio.

CEO Pascal Soriot declared upfront that he was "particularly pleased" with AstraZeneca PLC's performance in China in the first quarter, where he noted the UK-based multinational "continued to deliver double-digit sales growth."

More from Focus On Asia

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By 

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC

 

While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.

US-China Tariff War Pressures Pharma’s Complex Supply Chain

 
• By 

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.

More from Scrip

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

 

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By 

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By 

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.